Technology. Design and development of bacterial expression systems for peptide and proteins of customer choice.

Potential Industry Applications. Biomedical laboratory studies; products not approved for human use.

Advantages of APD Life Science’s Approach. Consultation with customer defines desired end-scale production needs and cost limitations. System is designed to match needs and a phased-approach with customer-controlled end-points to guide progress.

General Process Description. User specified needs help us to develop test vector(s) for expression in E coli. Test "matrix designed" approaches are used to identify likely combinations of host strain, temperature of induction and inducer concentration likely for success, with special emphasis on minimizing inclusion body formation when these are not desired. Small scale [<250 mL] approaches used to develop probable purification approaches. Scale up to 20 L fermentor available. Structure confirmation available via HPLC/MS analysis. Consulting available to guide scale up to larger quantities.

Service Status. Procedures are "up-and-running" and validated by production of gram quantities of end product.

Who is APD Life Science? A successor to BioPore, Inc., and formed in 2003 by Roy H. Hammerstedt, PhD, an Emeritus Professor at Penn State University with 40 years of experience in chemistry/physiology. Poised to license four technologies to end users on behalf of BioPore and/or APD Life Sciences. Developed and completed two NIH Phase-II SBIR grants [detection of bacteria in platelet containers, and cryostorage of cells and tissues].

APD Life Science’s Business Model. After in-house development and validation, license of protocols for large scale applications is recommended. Provision of application-specific consulting on an "as requested" basis. See the APD Life Science standard sub-licensing term sheet for key features to be negotiated.

To return to Current Services Offerings page, click here.

To see Overview of Approach, click here.